Linvoseltamab-Gcpt

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor).

An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor).

Journal: Expert review of hematology

Published: March 19, 2026

Linvoseltamab (Lynozyfic) for multiple myeloma.

Linvoseltamab (Lynozyfic) for multiple myeloma.

Journal: The Medical letter on drugs and therapeutics

Published: August 12, 2025

Lynozyfic (Linvoseltamab): A First-in-Class Off-the-Shelf T-Cell Redirector for Refractory Multiple Myeloma.

Lynozyfic (Linvoseltamab): A First-in-Class Off-the-Shelf T-Cell Redirector for Refractory Multiple Myeloma.

Journal: EJHaem

Published: July 18, 2025

Linvoseltamab: First Approval.

Linvoseltamab: First Approval.

Journal: Drugs

Published: June 22, 2025

Showing 1-4 of 4

Last Updated: 04/28/2026